Erica Chilson, United States of America
Pfizer Inc. Medical and Scientific AffairsPoster Author Of 1 e-Poster
COVERAGE OF THE 20-VALENT CONJUGATE VACCINE AGAINST INVASIVE PNEUMOCOCCAL DISEASE BY AGE GROUP IN THE UNITED STATES, 2017
Author Of 4 Presentations
TWENTY YEAR IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE ON INVASIVE PNEUMOCOCCAL DISEASE SYNDROMES IN US CHILDREN LESS THAN 5 YEARS OF AGE (ID 243)
- Ruth Chapman, United Kingdom
- Kelly Sutton, United Kingdom
- Rotem Lapidot, United States of America
- Erica Chilson, United States of America
- Vincenza Snow, United States of America
- Shreeya Patel, United Kingdom
- Des Dillon-Murphy, United Kingdom
- Raymond A. Farkouh, United States of America
- Margaret Moffatt, United States of America
- Matt Wasserman, United States of America
- Stephen I. Pelton, United States of America
CURRENT AND FUTURE PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPE-SPECIFIC BURDEN IN THE UNITED STATES ADULT POPULATION (ID 287)
Abstract
Background
An investigational 20-valent pneumococcal conjugate vaccine (PCV20) is in development and contains the 13 serotypes in PCV13, with 7 additional serotypes 22F,33F,8,10A,11A,12F and 15B. We estimated the epidemiologic and economic burden of pneumococcal disease attributable to serotypes contained in PCV13 and PCV20 for US adults.
Methods
The burden of disease was estimated using published and unpublished data on incidence rates, serotype coverage, mortality, and costs for invasive pneumococcal disease (IPD) and pneumonia. Active Bacterial Core surveillance data from 2017 was used for IPD data. Data was extrapolated to the total US adult population, stratified by age and risk group.
Results
Results are summarized in Table. An additional 9,900 cases of IPD, 44,000 cases of inpatient pneumonia, 52,000 cases of outpatient pneumonia, and 4,300 death are estimated to be caused by the seven new serotypes in PCV20. The new serotypes account for approximately 40% of all cases, deaths, and costs. Direct costs attributed to all PCV20 serotypes are estimated at $4.2 billion.
Conclusions
Pneumococcal disease remains an unmet need in US adults despite increasing uptake with PCV13 and 23-valent polysaccharide vaccine. The seven new serotypes contribute substantially to the clinical and economic burden of pneumococcal disease in adults.
ESTIMATED PNEUMOCOCCAL DISEASE AND ECONOMIC BURDEN FOR CURRENT AND FUTURE VACCINE SEROTYPES IN UNITED STATES IN CHILDREN UNDER FIVE YEARS OF AGE. (ID 288)
Abstract
Background
The 13-valent PCV (PCV13) has reduced vaccine preventable pneumococcal disease caused by serotypes 4,6B,9V,14,18C,19F,23F1,5,7F,3,6A,19A, with cross-protection against 6C. However, non-vaccine type burden remains in the United States (US). Higher-valent PCVs in development will contain additional serotypes 22F,33F,8,10A,11A,12F, and 15B (PCV20). We estimated the remaining clinical and economic burden attributed to current and future vaccine serotypes in US children under five.
Methods
The burden of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) was estimated by extrapolating the IPD serotype distribution from 2017 CDC Active Bacterial Core (ABC) surveillance data for PCV13 serotypes (25.0%) and PCV20 serotypes (58.1%) to current population statistics for all clinical entities. Clinical, epidemiologic, and costs data were sourced or estimated from published evidence.
Results
The estimated burden associated with PCV13 and PCV20 serotypes are in Table 1. Based on assumptions, the incremental burden is 700,000 disease cases and 69 deaths annually caused by additional serotypes contained in PCV20. This represented $445 million incremental annual direct costs in 2019 dollars.
Conclusions
Future PCV serotypes encompass a considerable amount of the disease burden. US infant pneumococcal disease and healthcare expenditure may be reduced if future PCVs provide comparable levels of protection as PCV13 serotypes.
COVERAGE OF THE 20-VALENT CONJUGATE VACCINE AGAINST INVASIVE PNEUMOCOCCAL DISEASE BY AGE GROUP IN THE UNITED STATES, 2017 (ID 237)
Abstract
Background
The United States experienced a substantial reduction in the incidence of invasive pneumococcal disease (IPD) following the introduction of pneumococcal conjugate vaccines (PCVs), PCV7 in 2000 and PCV13 in 2010, yet, disease remains. Expanded valency PCVs, PCV15 and PCV20 that contain two and seven additional serotypes compared to PCV13, are in advanced development.
Methods
We used the CDC Active Bacterial Core surveillance (ABCs) data from 2017 to quantify the incidence and to assess PCV coverage of IPD. ABC is an active laboratory and population-based surveillance system in 10 geographically diverse sites in the United States. Analyses were limited to the serotypes covered by PCV13 (1,3,4,5,6A,6B, 7F,9V,14,18C,19A,19F,23F, plus 6C, which is highly-related to 6A), PCV15 (PCV13-types, 22F,33F), and PCV20 (PCV15-types, 8,10A,11A,12F, plus 15C, which is highly-related to 15B).
Results
In 2017, non-PCV13 and PCV13 serotypes accounted for 63.1-75.0% and 25.0-36.9% of IPD cases across different age groups. The additional two serotypes in PCV15 and the seven serotypes in PCV20 accounted for 8.3-17.0% and 23.8-37.1% of the remaining IPD cases, respectively (Table).
Conclusions
PCV20 could address a substantial remaining burden of IPD, covering an estimated 55.1-66.1% of cases across all age groups.